SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Early Stage Parkinson Disease Clinical Trial

Official title: A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.

Status Completed

Clinical Trial Summary

This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Early Stage Parkinson Disease
• Parkinson Disease

• NCT number: NCT00335166
• Study type: Interventional
• Source: Solvay Pharmaceuticals
• Status: Completed
• Phase: Phase 3
• Start date: November 2006
• Completion date: February 2008